Fortrea has signed a definitive agreement to acquire the Early Phase Services division from Worldwide Clinical Trials for approximately $45 million. The acquisition includes bioanalytical laboratories in Austin, a 200-bed clinical pharmacology unit in San Antonio, and biospeci­men storage facilities in Pflugerville, Texas. This deal strengthens Fortrea's early-stage clinical development platform and integrated capabilities, while allowing Worldwide to focus on its faster-growing late-stage business across oncology, neuroscience, and rare diseases.

Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in cash. The acquisition includes a GLP-certified bioanalytical laboratory in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biosampling storage facility in Pflugerville, Texas. This strategic move strengthens Fortrea's early-stage clinical development platform and enables integrated Phase I-IV services, while allowing Worldwide to focus on its rapidly growing advanced-stage development business in oncology, neurociencia, and rare diseases.

Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP-compliant bioanalytical lab in Austin, a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, and a biorepository facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform from Phase I through Phase IV trials, while allowing Worldwide to focus on its rapidly growing late-stage business in oncology, neuroscience, internal medicine, and rare diseases.

Fortrea hat eine verbindliche Vereinbarung zum Erwerb des Geschäftsbereichs 'Frühe klinische Entwicklung' von Worldwide Clinical Trials für etwa 45 Millionen US-Dollar abgeschlossen. Die Übernahme umfasst ein GLP-konformes bioanalytisches Labor in Austin, eine klinisch-pharmakologische Abteilung mit 200 Betten in San Antonio und ein Bioprobenlager in Texas. Dies stärkt Fortreas Position als führender globaler Partner für klinische Entwicklung und ermöglicht integrierte Lösungen für frühe klinische Phasen.

Fortrea has agreed to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP-compliant bioanalytical laboratory in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biological sample storage facility in Pflugerville, Texas. This strengthens Fortrea's end-to-end clinical development platform with integrated bioanalytical capabilities for both large and small molecules, while allowing Worldwide to focus on its growing advanced-stage development activities in oncology, neurosciences, internal medicine, and rare diseases.

Fortrea has signed a definitive agreement to acquire Worldwide Clinical Trials' Early Phase Services division for approximately $45 million in cash. The acquisition includes a GLP bioanalytical lab in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biosampling facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform and early-stage capabilities, while allowing Worldwide to focus on its faster-growing late-stage business in oncology, neuroscience, internal medicine, and rare diseases.

Fortrea has signed a definitive agreement to acquire Worldwide Clinical Trials' Early Phase Services division for approximately $45 million in cash. The acquisition includes a GLP-compliant bioanalytical laboratory in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biological sample storage facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform and early-stage capabilities, while allowing Worldwide to focus on its rapidly growing late-stage development business in oncology, neuroscience, internal medicine, and rare diseases.

Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP-compliant bioanalytical laboratory in Austin, a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, and biospecimen storage facilities in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform from Phase 1 through Phase 4 trials and post-approval evidence generation, while allowing Worldwide to focus on its faster-growing late-stage clinical business in oncology, neuroscience, internal medicine, and rare diseases.

Fortrea has signed a definitive agreement to acquire Worldwide Clinical Trials' Early Phase Services division for approximately $45 million. The acquisition includes a GLP bioanalytical lab in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biospecimen storage facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform and expands its early-phase capabilities, while allowing Worldwide to focus on its rapidly growing late-phase business in oncology, neuroscience, and rare diseases.

Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP bioanalytical lab in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biosampling facility in Frugerville, Texas. The deal strengthens Fortrea's end-to-end clinical development platform and early-stage capabilities, while allowing Worldwide to focus on its rapidly growing late-stage business in oncology, neuroscience, internal medicine, and rare diseases.

Fortrea has signed a definitive agreement to acquire Worldwide Clinical Trials' Early Phase Services division for approximately $45 million in an all-cash transaction. The acquisition includes a 60,000 sq. ft. GLP bioanalytical lab in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biospecimen storage facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform and early-phase capabilities, while allowing Worldwide to focus on its rapidly growing late-stage business across oncology, neuroscience, internal medicine, and rare disease.

The global clinical trials market is projected to grow from $127.16 billion in 2025 to $176.32 billion by 2030, with a CAGR of 6.8%. Growth is driven by AI-enabled trial design, decentralized and virtual trials, precision medicine, and real-world evidence studies. North America leads the market while Asia-Pacific is the fastest-growing region. Strategic consolidation continues with major acquisitions strengthening end-to-end capabilities.